Drug Information

General Information
Drug ID
DR01164
Drug Name
Midodrine
Synonyms
(+-)-1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; (+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide monohydrochloride; (+-)-Midodrine hydrochloride; (+/-)-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; (-)-Midodrin hydrochloride; (-)-Midodrine hydrochloride; (RS)-N'-(beta-Hydroxy-2,5-dimethoxy-phenethyl)glycinamid; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; 1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamid; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethylacetamide; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide monohydrochloride; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hyyroxyethyl)acetamide monohydrochloride; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide hydrochloride; A 4020 Linz; A-4020 Linz; Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-, monohydrochloride; Acetamide, 2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)-, hydrochloride; Alphamine; Amatine; DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid; Gutron; Hipertan; MIDODRINE HYDROCHLORIDE; Metligene; Midamine; Midodrin; Midodrina; Midodrina [INN-Spanish]; Midodrine (INN); Midodrine HCL; Midodrine Monohydrochloride; Midodrine [BAN:INN]; Midodrine [INN:BAN]; Midodrine hydrochloride (JAN/USAN); Midodrine hydrochloride [USAN:JAN]; Midodrine hydrochloride [USAN]; Midodrinum; Midodrinum [INN-Latin]; N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]glycinamide; N-{2-[2,5-bis(methyloxy)phenyl]-2-hydroxyethyl}glycinamide; Pro-Amatine; Pro-Amatine (TN); ProAmatine; Proamatine (TN); ST-1085; St 1085; St. Peter 224; TS 701; [+/-]-1-[2,5-Dimethoxyphenyl]-2-glycinamidoethanol
Drug Type
Small molecular drug
Indication Prostate hyperplasia [ICD11: GA90] Approved [1]
Therapeutic Class
Vasoconstrictor Agents
Structure
3D MOL 2D MOL
Formula
C12H18N2O4
Canonical SMILES
COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O
InChI
InChI=1S/C12H18N2O4/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16)
InChIKey
PTKSEFOSCHHMPD-UHFFFAOYSA-N
CAS Number
CAS 133163-28-7
Pharmaceutical Properties Molecular Weight 254.28 Topological Polar Surface Area 93.8
Heavy Atom Count 18 Rotatable Bond Count 6
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 5
XLogP
-0.6
PubChem CID
4195
PubChem SID
10092 , 104305704 , 11336130 , 11361369 , 11364535 , 11367097 , 11369659 , 11372749 , 11373902 , 11377821 , 11462341 , 11466219 , 11467339 , 11485126 , 11485798 , 11489361 , 11491400 , 11492007 , 11495455 , 124963568 , 125684389 , 128965708 , 134222029 , 134337543 , 135002277 , 137240087 , 137248546 , 142173049 , 14847816 , 29223300 , 46507373 , 47365278 , 47365279 , 47662374 , 47736573 , 47810835 , 48035214 , 48259327 , 48416280 , 49698958 , 50064787 , 50122851 , 50122852 , 50949507 , 56464179 , 57322186 , 7433691 , 8152622 , 85788446 , 96024908
ChEBI ID
ChEBI:6933
TTD Drug ID
D02XJY
DT(s) Transporting This Drug PEPT1 Transporter Info Peptide transporter 1 Substrate [2]
References
1 Midodrine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.